These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21986085

  • 1. Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response.
    Kaiser RS, Gupta OP, Regillo CD, Ho AC, Fineman MS, Vander JF, McNamara JA, Brown GC.
    Ophthalmic Surg Lasers Imaging; 2012; 43(1):13-9. PubMed ID: 21986085
    [Abstract] [Full Text] [Related]

  • 2. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 3. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [Abstract] [Full Text] [Related]

  • 4. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB.
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [Abstract] [Full Text] [Related]

  • 5. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K, Pedersen TR, Sandvik L, Bragadóttir R.
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [Abstract] [Full Text] [Related]

  • 6. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H, Shah CP, Weber M, Heier JS.
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [Abstract] [Full Text] [Related]

  • 7. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS, Iordanous Y, Mao A, Powell AM, Kent SS, Sheidow TG.
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [Abstract] [Full Text] [Related]

  • 8. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration.
    Giansanti F, Bacherini D, Giacomelli G, Virgili G, Finocchio L, Fiore T, Vannozzi L, Menchini U.
    Eur J Ophthalmol; 2014 Oct; 24(3):402-8. PubMed ID: 24242217
    [Abstract] [Full Text] [Related]

  • 10. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
    Thorell MR, Nunes RP, Chen GW, Doshi RR, Dugar J, George MK, Kim BT, Lowrance MD, Modi D, Nahas Z, Gregori G, Yehoshua Z, Feuer W, Rosenfeld PJ.
    Ophthalmic Surg Lasers Imaging Retina; 2014 Oct; 45(6):526-33. PubMed ID: 25423632
    [Abstract] [Full Text] [Related]

  • 11. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [Abstract] [Full Text] [Related]

  • 12. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs.
    Bellerive C, Cinq-Mars B, Lalonde G, Malenfant M, Tourville E, Tardif Y, Giasson M, Hébert M.
    Can J Ophthalmol; 2012 Apr; 47(2):165-9. PubMed ID: 22560423
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration.
    Iordanous Y, Powell AM, Mao A, Hooper PL, Eng KT, Schwartz C, Kertes PJ, Sheidow TG.
    Can J Ophthalmol; 2014 Aug; 49(4):367-76. PubMed ID: 25103655
    [Abstract] [Full Text] [Related]

  • 14. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
    Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF, Comparison of Age-related Macular Degeneration Treatments Trials Research Group.
    Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002
    [Abstract] [Full Text] [Related]

  • 15. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 16. Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison.
    Pinheiro-Costa J, Freitas-da-Costa P, Falcão MS, Brandão EM, Falcão-Reis F, Carneiro AM.
    Ophthalmologica; 2014 May; 232(3):149-55. PubMed ID: 25196907
    [Abstract] [Full Text] [Related]

  • 17. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment.
    Witkin AJ, Rayess N, Garg SJ, Maguire JI, Storey P, Kaiser RS, Hsu J, Vander JF, Ho AC.
    Semin Ophthalmol; 2017 May; 32(3):309-315. PubMed ID: 26337539
    [Abstract] [Full Text] [Related]

  • 18. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.
    Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, Pauleikhoff D.
    Eye (Lond); 2009 Dec; 23(12):2163-8. PubMed ID: 19197318
    [Abstract] [Full Text] [Related]

  • 19. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S.
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [Abstract] [Full Text] [Related]

  • 20. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
    Holekamp NM, Liu Y, Yeh WS, Chia Y, Kiss S, Almony A, Kowalski JW.
    Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.